Evidence map›Paper›PMID 41103782›Full record

ArticleOpen forum infectious diseases2025

Features of Carbapenem-resistant Gram-negative Bacterial Infections in Japan Based on the Setting of Onset.

Yuya Kawamoto, Yusuke Asai, Aki Sakurai, Yasufumi Matsumura, Ryota Hase, Hideaki Kato, Takashi Matono, Naoya Itoh, Takehiro Hashimoto, Go Yamamoto and 12 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Open forum infectious diseases, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

22 authors.

Yuya KawamotoDepartment of Infectious Diseases, Fujita Health University School of Medicine, Aichi, Japan.
Yusuke AsaiAMR Clinical Reference Center, National Center for Global Health and Medicine, Japan Institute for Health Security, Tokyo, Japan.
Aki SakuraiDisease Control and Prevention Center, National Center for Global Health and Medicine, Japan Institute for Health Security, Tokyo, Japan.
Yasufumi MatsumuraDepartment of Clinical Laboratory Medicine, Kyoto University Graduate School of Medicine, Kyoto, Japan.ORCID https://orcid.org/0000-0001-8595-8944
Ryota HaseDepartment of Infectious Diseases, Japanese Red Cross Narita Hospital, Chiba, Japan.
Hideaki KatoInfection Prevention and Control Department, Yokohama City University Hospital, Kanagawa, Japan.ORCID https://orcid.org/0000-0002-7853-5721
Takashi MatonoDepartment of Infectious Diseases, Aso Iizuka Hospital, Fukuoka, Japan.
Naoya ItohDepartment of Infectious Diseases, Graduate School of Medical Sciences, Nagoya City University, Aichi, Japan.
Takehiro HashimotoHospital Infection Control Center, Oita University Hospital, Oita, Japan.
Go YamamotoDepartment of Infection Control and Prevention, The University of Osaka Hospital, Osaka, Japan.
Momoko MawatariDepartment of Infectious Diseases, Japanese Red Cross Medical Center, Tokyo, Japan.
Takeya TsutsumiDepartment of Infectious Diseases, The University of Tokyo Hospital, Tokyo, Japan.ORCID https://orcid.org/0000-0003-0851-1887
Tetsuya SuzukiDepartment of Infection Control and Prevention, University of Yamanashi Hospital, Chuo, Yamanashi, Japan.
Shinya TsuzukiAMR Clinical Reference Center, National Center for Global Health and Medicine, Japan Institute for Health Security, Tokyo, Japan.
Koji OhyamaDepartment of Microbiology, Fujita Health University School of Medicine, Aichi, Japan.
Masahiro SuzukiDepartment of Microbiology, Fujita Health University School of Medicine, Aichi, Japan.ORCID https://orcid.org/0000-0003-4550-3499
Kayoko HayakawaAMR Clinical Reference Center, National Center for Global Health and Medicine, Japan Institute for Health Security, Tokyo, Japan.
Kohei UemuraBiostatistics and Bioinformatics Course, The University of Tokyo, Tokyo, Japan.
David van DuinDivision of Infectious Diseases, University of North Carolina School of Medicine, Chapel Hill, North Carolina, USA.ORCID https://orcid.org/0000-0003-4784-3227
Norio OhmagariAMR Clinical Reference Center, National Center for Global Health and Medicine, Japan Institute for Health Security, Tokyo, Japan.
Yohei DoiDepartment of Infectious Diseases, Fujita Health University School of Medicine, Aichi, Japan.ORCID https://orcid.org/0000-0002-9620-2525
Sho SaitoDisease Control and Prevention Center, National Center for Global Health and Medicine, Japan Institute for Health Security, Tokyo, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Carbapenem-resistant Gram-negative bacilli (CR-GNB) are a major public health threat, traditionally linked to hospital settings. However, infections are increasingly reported in the community, and the clinical distinctions between community-associated (CA) and healthcare-associated (HA) infections remain unclear. Methods: We conducted a prospective multicenter study of hospitalized patients with CR-GNB infections across 13 Japanese tertiary hospitals between April 2019 and March 2024. Infections were categorized as CA, HA, or hospital-onset (HO) using standardized criteria. We compared patient demographics, microbiological findings, infection sites, and clinical outcomes based on the setting of onset. Results: Among 425 patients, 43 had CA, 59 HA, and 323 HO infections. Conclusions: Community-associated CR-GNB infections are an emerging concern in Japan, showing distinct pathogen profiles and infection sites compared to HO cases. Importantly, HA infections resembled CA infections in terms of clinical characteristics and outcomes, suggesting a need to reexamine the clinical relevance of current HA classification criteria for guiding therapy and risk stratification.

Indexed as

carbapenem-resistant Gram-negative bacilliclinical outcomescommunity-associated infectionhealthcare-associated infectionhospital-onset infection

Identifiers

PMID41103782
PMCPMC12527233

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.